Glucagon (medication)
Glucagon, sold under the brand name Baqsimi among others, is a medication and hormone. As a medication it is used to treat low blood sugar, beta blocker overdose, calcium channel blocker overdose, and those with anaphylaxis who do not improve with epinephrine. It is given by injection into a vein, muscle, or under the skin. A version given in the nose is also available.
Clinical data | |
---|---|
Trade names | Glucagen, Baqsimi, Gvoke, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682480 |
License data | |
Pregnancy category |
|
Routes of administration | Nasal, intravenous (IV), intramuscular injection (IM), subcutaneous injection |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C153H225N43O49S |
Molar mass | 3482.80 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(what is this?) (verify) |
Common side effects include vomiting. Other side effects include low blood potassium and low blood pressure. It is not recommended in people who have a pheochromocytoma or insulinoma. Use in pregnancy has not been found to be harmful to the baby. Glucagon is in the glycogenolytic family of medications. It works by causing the liver to break down glycogen into glucose.
Glucagon was approved for medical use in the United States in 1960. It is on the World Health Organization's List of Essential Medicines. It is a manufactured form of the glucagon hormone. A generic version became available in the United States in December 2020.